Could a cure for sluggish cognitive tempo be around the corner?



At least one drug company is targeting problematic daydreaming.
  • Chris Potter/
  • At least one drug company is targeting problematic daydreaming.
Have you been daydreaming lately? Does your mind wander? Is your thinking a little slow? You are not alone.

On Saturday, The New York Times reported on the growing research into sluggish cognitive tempo, a condition characterized by lethargy, daydreaming, and slow mental processing. It's similar to attention deficit hyperactivity disorder, but some researchers have found enough differences to argue that SCT is a separate disorder. Children with SCT tend to be less troublesome for adults than children with ADHD, for instance, according to these researchers. The SCT kids are "the daydreamy ones, the ones with work that's not turned in, leaving names off of papers or skipping questions," a researcher told the NYT.

The Times article was about SCT in children, but researchers have asserted that adults are susceptible, too. I have symptoms of SCT most mornings, which I have been treating homeopathically, at a Starbucks. Fortunately, a more reliable remedy may be on the way, because Eli Lilly is on the case. The drug company has funded a clinical trial to determine if Strattera, a Lilly drug used to treat ADHD, may be effective for SCT as well. A Lilly spokeswoman told the Times in an e-mail that SCT is "one of many conditions that Lilly scientists continue to study to help satisfy unmet medical needs around the world."

So before long we'll hear the commercials: "Ask your doctor if CONCENTRENDIA is right for you. . . . Take one CONCENTRENDIA 30 minutes before you need to focus. If a lack of concentration causes you to miss a doze, do not take an extra dose. Do not take CONCENTRENDIA with doppios or Mountain Dew—your mental processing may become uncomfortably rapid. Call your health care provider if you experience prolonged and uncontrollable concentration."

Comments (2)

Showing 1-2 of 2

Add a comment

Add a comment